Skip to main content

Published locations for Aleglitazar failed to reduce cardiovascular events in type 2 diabetes

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Aleglitazar failed to reduce cardiovascular events in type 2 diabetes

User login

  • Reset your password
  • /content/aleglitazar-failed-reduce-cardiovascular-events-type-2-diabetes
  • /familypracticenews/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events
  • /ehospitalistnews/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events
  • /internalmedicinenews/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular
  • /clinicalendocrinologynews/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular
  • /ecardiologynews/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events
  • /cardiology/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events-type-2
  • /endocrinology/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events-type
  • /internalmedicine/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events
  • /familymedicine/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular-events
  • /type-2-diabetes-icymi/article/81312/cad-atherosclerosis/aleglitazar-failed-reduce-cardiovascular